Provided by Tiger Trade Technology Pte. Ltd.

Personalis

16.10
-0.1900-1.17%
Volume:2.43M
Turnover:39.08M
Market Cap:1.72B
PE:-14.67
High:16.40
Open:16.15
Low:15.92
Close:16.29
52wk High:18.89
52wk Low:4.96
Shares:107.00M
Float Shares:72.63M
Volume Ratio:1.13
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0976
EPS(LYR):-0.9107
ROE:-50.32%
ROA:-25.03%
PB:7.33
PE(LYR):-17.68

Loading ...

Personalis Receives UK Regulatory Marking for Disease Detection Technology

MT Newswires Live
·
Jul 14

Personalis’ NeXT Personal test granted UKCA marking

TIPRANKS
·
Jul 14

Personalis Wins UKCA Mark for Next Personal Dx MRD Test in Great Britain

Reuters
·
Jul 14

Personalis CEO Christopher M. Hall Disposes of 100,000 Common Shares for $1.51 Million

Reuters
·
Jul 10

Personalis is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Personalis price target raised to $13 from $9 at Morgan Stanley

TIPRANKS
·
Jul 09

Personalis Cfo/coo Aaron Tachibana Disposes of 4,982 Common Shares for $69,748

Reuters
·
Jun 30

Personalis CEO Christopher M. Hall Disposes of 100,000 Common Shares Worth $1.32 Million

Reuters
·
Jun 27

Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data

Simply Wall St.
·
Jun 17

How Investors May Respond To Personalis (PSNL) CE Mark Win For Its MRD Blood Collection Kits

Simply Wall St.
·
Jun 15

A Look At Personalis (PSNL) Valuation After New ASCO Data On NeXT Personal MRD Platform

Simply Wall St.
·
Jun 09

Personalis Gains EU Approval for Blood Collection Kits Used in Genomic Testing

MT Newswires Live
·
Jun 09

Personalis blood collection kits win EU CE-IVD mark under IVDR

Reuters
·
Jun 09

Can Personalis (PSNL) Turn NeXT Personal’s Multi‑Tumor MRD Data Into Durable Competitive Advantage?

Simply Wall St.
·
Jun 08

Personalis CFO, COO Aaron Tachibana disposes of common shares worth $480,400

Reuters
·
Jun 06

Personalis' Cancer Monitoring Tool Shows Early Detection of Relapse

MT Newswires Live
·
Jun 02

Personalis NeXT Personal MRD test posts 100% sensitivity for colorectal cancer relapse in VICTORI study at ASCO 2026

Reuters
·
Jun 02

Personalis CEO Christopher M. Hall disposes of common shares worth $1,101,800.18

Reuters
·
May 30

Personalis CFO, COO Aaron Tachibana disposes of common shares valued at $449,248.42

Reuters
·
May 30

Personalis NeXT Personal ctDNA assay posts 100% longitudinal sensitivity for colorectal cancer recurrence in VICTORI study

Reuters
·
May 26